相关实验视频
Updated: Jun 19, 2025

06:08
Transcranial Pulse Stimulation for Alzheimer's Patients
Published on: April 4, 2025
510
西用于治疗阿尔茨海默氏症
Siyi Zheng1, Rong Ma2, Yang Yang3
1Department of Neurology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Frontiers in neuroscience
|July 25, 2024
概括
西通过增强神经可塑性和减少炎症,显示出对阿尔茨海默病 (AD) 治疗的潜力. 本综述探讨了AD管理的机制和治疗可能性.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 精神病学是一个精神病学.
背景情况:
- 阿尔茨海默病 (AD) 是导致痴呆的主要原因,治疗选择有限.
- 精神中的一种化合物psilocybin因其在治疗抑郁症的安全性和有效性而得到认可.
- 西在阿尔茨海默病的治疗潜力在很大程度上尚未被探索.
研究的目的:
- 审查psilocybin的药理作用.
- 检查现有证据,探讨psilocybin对AD产生积极影响的机制.
- 讨论psilocybin在管理AD症状和认知衰退中的潜在作用.
主要方法:
- 关于 псилоцибин的药理学和作用的综合文献综述.
- 分析研究的分析调查psilocybin对神经可塑性,炎症和认知功能的影响.
- 在AD的背景下,探索psilocybin对情绪和焦虑的影响.
主要成果:
- 西的活性代谢物psilocin调节了5-HT2A受体.
- 这种调制与增加的神经可塑性,减少炎症和改善认知灵活性有关.
- 西可以缓解AD患者的焦虑和抑郁症状.
结论:
- 西显示出对阿尔茨海默病的有前途的治疗潜力.
- 需要进一步的研究来确定最佳剂量和减轻不良影响.
- 伦理和法律方面的考虑对于西在阿尔茨海默病治疗中的临床应用至关重要.
更多相关视频
08:01Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits
Published on: March 16, 2016
42.2K
10:08Microtransplantation of Synaptic Membranes to Reactivate Human Synaptic Receptors for Functional Studies
Published on: July 20, 2022
2.2K
相关概念视频
Alzheimer's Disease: Treatment
172
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
172
Alzheimer's Disease: Overview
456
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
456
Parkinson's Disease: Treatment
244
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
244
iPS Cell Differentiation
2.7K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
2.7K